Mylan, Government Finalize EpiPen Settlement

Mylan has finalized a settlement to pay hundreds of millions of dollars to resolve claims it overcharged the government for the EpiPen. The U.S. Attorney's Office in Massachusetts today revealed the pharmaceutical company and the U.S. Justice Department have completed the $465-million settlement.  

The agreement resolves claims Mylan misclassified its emergency allergy treatment as generic rather than a branded product, resulting in underpaid rebates to Medicaid. 


Sponsored Content

Sponsored Content